Trial Profile
A Study evaluating the effects of the body surface area(BSA)-adjusted doses of dasatinib on molecular responses and dose-limiting toxicities in patients with chronic myeloid leukemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 25 Jul 2018 New trial record
- 17 Jun 2018 Results (n=101) presented at the 23rd Congress of the European Haematology Association